The Case for Psychedelics, Used With Intention

AUREA advocates for psychedelics used responsibly and intentionally: for personal growth, for better work, and for deeper connection with community and tribe. These medicines are returning to professional life faster than the law, the medical system, or the culture can keep up. Used with intention, they can change a life. Used to avoid one, they become another way to stay stuck.

This piece is written for professionals in Austin and beyond: founders, executives, coaches, and healers who are curious, or already experienced, and want an honest map. It covers what the research and the law actually say in Texas right now, where we think the current wave is going wrong, and what responsible work with these medicines requires.

Nothing here is medical or legal advice. It is a point of view, stated plainly.

Why are so many professionals turning to psychedelics?

Professionals are turning to psychedelics because the usual tools for burnout, anxiety, and meaninglessness are not reaching them. Talk therapy helps many people, but some arrive at year five of therapy still running the same pattern, and they are looking for something that works at a deeper level.

The pressure is real. In a 2025 Sifted survey of 138 startup founders, 54 percent reported burnout in the past year and 75 percent reported anxiety. It is a small sample, and it matches what we see. The people who carry the most weight often have the fewest places to set it down.

The use is also wider than most people think. RAND estimated in January 2026 that about 9.5 million U.S. adults microdosed psilocybin, LSD, or MDMA in the past year. Nobody has credible numbers on how many of them are executives, and we will not invent one. But anyone who has spent time in Austin's founder and wellness circles knows the conversation is no longer fringe.

What is the legal status of psychedelics in Texas?

Psilocybin is still illegal in Texas, and possessing any amount is a felony. Texas law places psilocybin in Penalty Group 2 of the Health and Safety Code, and Austin has never passed a psychedelic decriminalization measure. The 2020 Austin City Council resolution people sometimes cite was about marijuana.

At the same time, the state is funding psychedelic research. In 2025 Texas passed SB 2308, which set aside $50 million for FDA-track ibogaine trials, aimed at opioid addiction and brain injury in veterans. In March 2026, after no drug company met the law's terms, state leaders said Texas would run the program itself through UTHealth Houston and UTMB. As of this writing, no trial start date is public.

Earlier, in 2021, HB 1802 ordered a Texas study of psilocybin, MDMA, and ketamine for veterans with PTSD. The Baylor College of Medicine trial began in January 2025 and was still recruiting in early 2026. There are no published results yet.

Ketamine is the exception that is already legal. It is a prescription drug, and ketamine clinics operate across Austin. The Texas Medical Board has proposed tighter rules for those clinics.

So the honest summary for a Texas professional is this. The state is spending real money because it believes these medicines may work, and it will still prosecute you for possessing them outside a trial.

Where does federal approval of MDMA and psilocybin stand?

Neither MDMA nor psilocybin is FDA-approved for any use as of October 2026, though both are close to a decision. The FDA rejected MDMA-assisted therapy for PTSD in August 2024 after an advisory panel voted 10 to 1 against it. The company, now called Resilient Pharmaceuticals, reportedly refiled in August 2026 without a new trial.

Compass Pathways is further along with psilocybin for treatment-resistant depression. It received a fast-track review in April 2026 and expects to complete its FDA filing in the fourth quarter of 2026, with a launch targeted for the first half of 2027 if approved.

That timing matters. A legal, clinic-based psilocybin option may exist within the next year. It will be expensive, narrow, and medical. Many people will not wait for it, which is exactly why the next two sections matter.

What did Dr. James Fadiman discover about psychedelics and professional creativity?

Dr. James Fadiman, a Stanford-trained psychologist, helped run one of the first studies of psychedelics and professional problem-solving, and later did more than anyone to bring microdosing into the mainstream. Much of today's conversation about psychedelics for professionals traces back to his work.

In the early 1960s, Fadiman was finishing his psychology doctorate at Stanford and working with the International Foundation for Advanced Study in Menlo Park, California. It was an engineering culture, far from the counterculture. Its founder, Myron Stolaroff, had been an executive at Ampex, and its researchers included Stanford engineering professor Willis Harman and Stanford design professor Robert McKim.

Their 1966 pilot study, "Psychedelic Agents in Creative Problem-Solving," published in Psychological Reports, gave 27 working engineers, physicists, mathematicians, architects, and designers a moderate dose of mescaline in a carefully structured day. Each man brought real professional problems he had been stuck on for months. The first hours were spent lying down with eyeshades and music, with explicit instructions not to work on the problem. Only then did participants turn to their work, in silence, followed by written reports and follow-up interviews in the weeks after.

The results were striking and fragile at once. By the participants' own accounts, 6 of the 44 problems they brought led to solutions that reached production or commercial development, and about 20 more opened new lines of investigation. The study had no control group, no placebo, and self-reported outcomes. Federal restrictions closed the research before a larger follow-up could run.

Decades later, Fadiman's 2011 book, The Psychedelic Explorer's Guide, made microdosing a household word. He described a simple protocol, a very small dose one day followed by two days off, and collected reports from people around the world who said it helped their mood, focus, and creativity.

What does modern research say about psychedelics and performance?

Modern controlled research supports some of Fadiman's claims and complicates others, and an honest advocate should know both. In a 2021 placebo-controlled study of 60 people at Maastricht University, published in Translational Psychiatry, participants on psilocybin performed worse on some thinking tasks during the session while feeling far more insightful, then showed improved divergent thinking a week later. That fits Fadiman's long-held view that the benefit shows up in the weeks after a session more than during it.

Microdosing is harder to pin down. The largest placebo-controlled microdosing study to date, a 2021 self-blinding study of 191 people published in eLife, found that the microdose group and the placebo group both improved on psychological measures, with no significant difference between them.

We read that as support for our position. Intention, expectation, structure, and follow-through carry much of the effect. The most durable lessons of the 1966 study were about the container: bring a real problem, step away from it on purpose, protect the time, write down what comes, and act on it. Any professional can build that.

Can psychedelics help with productivity?

Psychedelics can support better work when they are used with intention, and AUREA says so openly. Many people report sharper focus, more creative thinking, and more energy for work that matters to them. Intention is what separates that from a habit that quietly costs you.

The useful question is what kind of productivity you are after. Productivity in service of your purpose, the work you were made for, is worth pursuing with every good tool available. Productivity in service of a life that is breaking you is something else. A dose taken before a board meeting so you can keep ignoring that the company is slowly killing you turns a tool built for revelation into a way of not looking.

The deepest value these medicines have shown, in research and in traditional use, is that they tend to show people what they have been refusing to see. Let them. The best work of your life usually starts on the other side of that honesty.

So set the intention before anything else. Write down what you want to understand, change, or create, and who will help you hold it afterward. If the honest answer is "to keep going without changing anything," that answer is the work.

What the underground retreat economy gets wrong

The underground psychedelic retreat economy too often sells a peak experience without the screening before it or the integration after it. That is the part we consider dangerous, more than the medicine itself.

A typical pattern: a beautiful property, a charismatic facilitator, a weekend price, a group of strangers, and no medical intake. People fly home Monday into the same marriage, the same job, and the same isolation, carrying an experience that may have cracked something open with no one around to help them make sense of it.

The risks are not theoretical. Ibogaine carries known cardiac risk, which is one reason Texas researchers expect full drug development to cost well over $100 million. Clinical trials of psilocybin routinely exclude people with a personal or family history of psychosis or bipolar disorder. Certain psychiatric medications interact with these substances. A weekend retreat that skips those questions is gambling with someone else's mind.

And in Texas, there is the law. Underground work means every participant and facilitator is carrying felony risk, usually without having been told so plainly.

What responsible psychedelic work requires

Responsible psychedelic work requires three things the market keeps trying to skip: honest screening, a real container, and long integration. The medicine is the shortest part of the process.

Screening. Medical and psychiatric history, current medications, heart health where it matters, and an honest conversation about why now. A good guide turns some people away. If no one has ever turned anyone away, that tells you something.

Container. Skilled people, a safe setting, clear agreements about consent and touch, and a plan for when things get hard. Experienced guides talk about set and setting for a reason. Your state of mind and your surroundings shape the experience as much as the substance does.

Integration. Weeks and months, not an hour on Sunday. Integration means turning what you saw into actual changes: a hard conversation you finally have, a business you restructure, a habit you end. It is best done with people who know you and will still be there next month.

That last point is the one most often missing, and it is the one community solves. You cannot integrate alone what you were never supposed to carry alone.

Where AUREA stands on psychedelics

AUREA advocates for psychedelics being used responsibly and intentionally for personal growth, productivity, and community and tribal connection. We support legal, research-backed access, and we think the Texas investment in ibogaine research is a good thing.

We also think the current professional wave is at risk of turning sacred medicine into a shortcut, and we will say that out loud even when it is unpopular in our own circles. Responsible and intentional are the two words that carry our whole position.

Our stand comes down to six commitments.

We are honest that this is part of many of our people's lives. Plenty of the healers, guides, and leaders in the AUREA community have worked with these medicines, and some of their talks on our stage speak to it directly. Pretending otherwise would be a lie.

We advocate for intentional use. Personal growth, better work, and deeper connection are all worthy reasons to work with these medicines, when the intention is clear, the preparation is real, and the integration is honest.

We value connection as much as insight. Some of the most important effects people describe are relational: feeling close to others again, repairing a bond, remembering they belong to a people. Traditional cultures have long worked with these medicines in community. We think that wisdom matters.

We put transformation ahead of experience. Anyone can have a powerful night. The work we care about is who you become in the months after it.

We build the integration layer. Breathwork, small circles, honest conversation, and a community that is still there on Monday. At AUREA IV: The Next Renaissance, every guest is matched into a Penta, a small circle of up to five people who hold you to what you decide. That kind of structure is what most people coming out of a medicine experience are missing.

We respect the law and push to change it. Nothing in this article is an offer of medicine, and we will never treat these substances casually. We will keep supporting the research and the reforms that make careful, legal access possible.

If you are carrying something heavy right now, start with people, not a substance. In the United States, calling or texting 988 reaches the Suicide and Crisis Lifeline at any hour.

Frequently asked questions

Is psilocybin legal in Austin?

No. Psilocybin is illegal throughout Texas, including Austin, and possessing any amount is a felony under the Texas Health and Safety Code. Austin has not passed a psychedelic decriminalization measure; the 2020 city council resolution on low-level arrests applied to marijuana. Texas is funding ibogaine research and studying psilocybin for veterans with PTSD, but those programs run only inside approved clinical trials.

Can psychedelics help professionals be more productive?

Many people report sharper focus, more creativity, and renewed energy for meaningful work, and AUREA advocates for intentional use toward those ends. Safety depends on your health history and medications, these substances are illegal in Texas outside approved trials, and this article is not medical advice. The key is intention: productivity in service of your purpose, not a way to keep performing in a life that is burning you out.

What is the Fadiman microdosing protocol?

The Fadiman protocol, described by psychologist Dr. James Fadiman in his 2011 book The Psychedelic Explorer's Guide, involves a very small, sub-perceptual dose of a psychedelic one day, followed by two days off, repeated for several weeks. Many people have reported better mood, focus, and creativity. A 2021 placebo-controlled study found similar improvements in placebo users, which suggests intention and expectation play a large role. These substances remain illegal in Texas.

What is psychedelic integration?

Psychedelic integration is the work of turning what you experienced into lasting changes in how you live. It happens over weeks and months after a session, through reflection, honest conversation, and concrete decisions about relationships, work, and habits. Integration is usually more effective with skilled support and a community that knows you, which is why AUREA builds small, ongoing circles rather than one-time experiences.

What is Texas doing with ibogaine?

In 2025 Texas passed SB 2308, which set aside $50 million for FDA-track clinical trials of ibogaine, mainly for opioid addiction and brain injury in veterans. In March 2026, after no drug company met the law's terms, state leaders said Texas would run the program itself through UTHealth Houston and UTMB. Ibogaine carries known heart risks, and no public trial start date had been announced as of October 2026.

How does AUREA approach psychedelic medicine?

AUREA advocates for psychedelics used responsibly and intentionally for personal growth, productivity, and community and tribal connection, and supports legal, research-backed access. Nothing on this site is an offer of medicine. AUREA's focus is the part most people are missing: breathwork, honest community, and small circles called Pentas that help leaders integrate what they have lived through and turn it into real change in their work and lives.